skip to Main Content

Pancreatic Cancer Immune Checkpoint Target Identified

Newsfeed image, light gray text on dark gray background
While current immune checkpoint inhibitor therapies are largely ineffective against pancreatic cancer, scientists in the U.S. have now identified an immune checkpoint molecule that could represent a promising immunotherapeutic target for this tumor type.

The University of Texas MD Anderson Cancer Center-led team found that V-domain immunoglobulin suppressor of T cell activation (VISTA) is preferentially expressed at high levels in pancreatic cancer, when compared with melanoma tumors. The researchers’ studies also provided a detailed analysis of immune infiltration in primary and metastatic pancreatic cancers, in comparison with melanoma, which could further help to direct immunotherapy strategies against pancreatic cancer treatment. Read more. . .

Back To Top